Paradigm shifts in metastatic hormone sensitive prostate cancer (mHSPC): Recent treatment developments
The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is rapidly changing.
|Organiser||European School of Urology (ESU)|
|Duration||Approx 60 minutes|
In this e-course we will address the following questions:
- Is PSMA-PET scan the preferred imaging modality in mHSPC or are bone and CT scans sufficient?
- What is the best treatment for men with mHSPC? Is it the combination treatment of androgen deprivation therapy (ADT) plus docetaxel or an androgen receptor signaling inhibitor (ARSi) or triplet therapy? Are any of these combination treatments for high-volume disease only?
- What is the indication for adding radiotherapy?
- Is there a difference between treatment for de novo disease or recurrent disease after treatment of the primary tumour?
Contact our organiser
European School of Urology (ESU)